In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases
(IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus …

Objective: Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy
in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in …

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …

Background Janus kinase (JAK)‐mediated cytokine signalling contributes to local and
systemic inflammation in hidradenitis suppurativa (HS). Objectives To describe the safety …

Objectives To provide an integrated analysis of major adverse cardiovascular events
(MACEs) and events of venous thromboembolism (VTE) and associated risk factors across …

Introduction The benefit/risk profiles of biologics can be affected by comorbidities, certain
demographic characteristics, and concomitant medications; therefore, it is important to …

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease, of which the leading
cause of death is cardiovascular disease (CVD). The levels of total cholesterol (TC), low …

ABSTRACT Introduction Janus Kinase inhibitors (JAKi) have shown to be highly effective in
the treatment of immune-mediated inflammatory diseases. As with all immunomodulatory …

Background Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the
treatment of rheumatoid arthritis (RA). JAK inhibitors have been associated with an …

JAK-STAT cytokines are critical in regulating immunity. Persistent activation of JAK-STAT
signaling pathways by cytokines drives chronic inflammatory diseases such as asthma …